1-苄基-2-氯苯并咪唑 | 43181-78-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 1-苄基-2-氯苯并咪唑
• 中文别名: 1-苄基-2-氯-1H-苯并咪唑
• 英文名称: 1-benzyl-2-chlorobenzimidazole
• 英文别名: 1-benzyl-2-chloro-1H-benzo[d]imidazole；N-benzyl-2-chlorobenzimidazole；1-Benzyl-2-chlor-benzimidazol
• CAS: 43181-78-8
• 化学式: C₁₄H₁₁ClN₂
• 分子量: 242.708
• InChiKey: PVLIRTAXXPPHCJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温、密闭保存，并置于干燥处。

反应信息

• 作为反应物：
  描述：

  1-苄基-2-氯苯并咪唑 在 palladium on activated charcoal ammonium formate 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 72.0h， 生成 n-丁基-(9ci)-1H-苯并咪唑-2-胺
  参考文献：
  名称：

  The high-pressure SNAr reaction of N-p-Fluorobenzyl-2-chlorobenzimidazole with amines; an approach to norastemizole and analogues

  摘要：

  N-p-fluorobenzyl-2-chlorobenzimidazole was treated under hyperbaric conditions with a variety of primary and secondary amines. The resulting SNAr reaction proceeded smoothly to produce excellent yields of adducts in most cases. This methodology provides rapid access to astemizole, norastemizole and related analogues. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(99)00290-7
• 作为产物：
  描述：

  N1-苄基苯-1,2-二胺 在 盐酸 、 三氯氧磷 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 生成 1-苄基-2-氯苯并咪唑
  参考文献：
  名称：

  Synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-a]benzimidazole derivatives against Leishmania donovani and Trypanosoma cruzi

  摘要：

  A high-throughput (HTS) and high-content screening (HCS) campaign of a commercial library identified 2,3-dihydroimidazo[1,2-a]benzimidazole analogues as a novel class of anti-parasitic agents. A series of synthetic derivatives were evaluated for their in vitro anti-leishmanial and anti-trypanosomal activities against Leishmania donovani and Trypanosoma cruzi, which have been known as the causative parasites for visceral leishmaniasis and Chagas disease, respectively. In the case of Leishmania, the compounds were tested in both intracellular amastigote and extracellular promastigote assays. Compounds 4 and 24 showed promising anti-leishmanial activity against intracellular L. donovani (3.05 and 5.29 μM, respectively) and anti-trypanosomal activity against T. cruzi (1.10 and 2.10 μM, respectively) without serious cytotoxicity toward THP-1 and U2OS cell lines.

  DOI：

  10.1016/j.ejmech.2014.07.038

文献信息

• Synthesis of novel substituted 3-(4-((1H-benzo[d]imidazol-2-ylthio)methyl)-1-phenyl-1H-pyrazol-3-yl)-2H-chromen-2-ones: various approaches
  作者：Devulapally Srikrishna、Pramod Kumar Dubey

  DOI：10.1007/s11164-018-3397-x

  日期：2018.7

  a privileged structure for developing probes of impressive pharmacological potentials, some new coumarin and pyrazole conjugates of benzimidazoles were synthesized with a sulphur linkage. Thus, 3-(2-oxo-2 H -chromen-3-yl)-1-phenyl-1 H -pyrazole-4-carbaldehyde ( 3 ) was prepared starting from simple salicylaldehyde which has been used as an important synthon and incorporated in a series of structural

  摘要以 苯并咪唑为优先结构，可开发出令人印象深刻的药理潜力的探针，合成了一些新的具有硫键的苯并咪唑香豆素和吡唑共轭物。因此，3-（2-氧代-2- ħ -苯并吡喃-3-基）-1-苯基-1- ħ 吡唑-4-甲醛（ 3 ）的制备从已经作为重要的合成子和并入简单水杨醛开始在一系列结构操作中获得各种药效基序缀合物 9（a–b） 和 13（a–f） ，以合理的收益率。我们已经开发出了简便且逐步的方法，可以通过各种方法合成所有这些化合物，其中还涉及子序列。通过IR，1 HNMR，13 CNMR和质谱数据很好地表征了所有合成的化合物。 图形概要
• Efficient Transposition of the Sandmeyer Reaction from Batch to Continuous Process
  作者：Joseph D’Attoma、Titi Camara、Pierre Louis Brun、Yves Robin、Stéphane Bostyn、Frédéric Buron、Sylvain Routier

  DOI：10.1021/acs.oprd.6b00318

  日期：2017.1.20

  The transposition of Sandmeyer chlorination from a batch to a safe continuous-flow process was investigated. Our initial approach was to develop a cascade method using flow chemistry which involved the generation of a diazonium salt and its quenching with copper chloride. To achieve this safe continuous process diazotation, a chemometric approach (Simplex method) was used and extrapolated to establish

  研究了桑德迈尔氯化法从批次到安全连续流过程的转换。我们最初的方法是开发一种使用流化学的级联方法，该方法涉及重氮盐的生成并用氯化铜淬灭。为了实现这种安全的连续过程重氮化，使用了化学计量方法（Simplex方法）并外推以建立完全连续流方法。还通过合成几种（杂）芳基氯来检查反应范围。还对过程进行了验证和放大。在提高安全性的同时获得了更高的生产率。
• Intermolecular [2 + 2] Photocycloaddition of α,β-Unsaturated Sulfones: Catalyst-Free Reaction and Catalytic Variants
  作者：Noah Jeremias、Lisa-Marie Mohr、Thorsten Bach

  DOI：10.1021/acs.orglett.1c01794

  日期：2021.8.6

  2-Aryl-1-sulfonyl-substituted cyclobutanes were prepared in an intermolecular [2 + 2] photocycloaddition from various α,β-unsaturated sulfones and olefins upon irradiation at λ = 300 nm (26 examples, 60–99% yield). Lewis acids catalyzed the [2 + 2] photocycloaddition of 2-benzimidazolyl styryl sulfones. At short wavelengths, the latter substrates underwent C–S bond cleavage but AlBr3 (5 mol %) allowed

  2-Aryl-1-磺酰基取代的环丁烷是在 λ = 300 nm 照射下，通过分子间 [2 + 2] 光环加成反应制备的（26 个例子，产率 60-99%）。路易斯酸催化 2-苯并咪唑基苯乙烯基砜的 [2 + 2] 光环加成。在短波长下，后一种底物经历 C-S 键断裂，但 AlBr 3 (5 mol %) 允许在较长波长下与 2,3-二甲基-2-丁烯发生分子间反应。手性金属路易斯酸（2 mol%）促进了对映选择性反应（高达 77% ee）。
• Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
  申请人：Bayer Pharmaceuticals Corporation

  公开号：US20040224997A1

  公开（公告）日：2004-11-11

  This invention relates to certain aryl alkyl acid compounds, compositions, and methods for treating or preventing obesity and related diseases.

  这项发明涉及某些芳基烷基酸化合物、组合物以及治疗或预防肥胖和相关疾病的方法。
• Bis (benzimidazole) derivatives serving as potassium blocking agents
  申请人：Neurosearch A/S

  公开号：US06194447B1

  公开（公告）日：2001-02-27

  This invention relates to novel potassium channel blocking agents, and their use in the preparation of pharmaceutical compositions. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels, in particular asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, irritable bowel syndrome, gastrointestinal dysfunction, secretory diarrhoea, ischaemia, cerebral ischaemia, ischaemic hearth disease, angina pectoris, coronary hearth disease, traumatic brain injury, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, dysmenorrhea, narcolepsy, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, migraine, arrhythmia, hypertension, absence seizures, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labor, baldness, cancer, and immune suppression.

  这项发明涉及新型钾通道阻滞剂，以及它们在制备药物组合物中的应用。 此外，该发明针对用于治疗或缓解与钾通道活性相关的疾病或障碍的药物组合物，特别是哮喘、囊性纤维化、慢性阻塞性肺病和鼻涕、痉挛、血管痉挛、冠状动脉痉挛、肾脏疾病、多囊肾病、膀胱痉挛、尿失禁、膀胱排出道梗阻、肠易激综合征、胃肠功能障碍、分泌性腹泻、缺血、脑缺血、缺血性心脏病、心绞痛、冠状动脉心脏病、创伤性脑损伤、精神病、焦虑、抑郁症、痴呆、记忆和注意力缺陷、阿尔茨海默病、痛经、嗜睡症、雷诺氏病、间歇性跛行、Sjorgren综合征、偏头痛、心律失常、高血压、缺席性癫痫发作、肌肉肌无力症、口干症、糖尿病II型、胰岛素过多症、早产、秃头、癌症和免疫抑制。